Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Beckman Coulter to Distribute Xtrana s DNA Extraction Technology

NEW YORK, Jan 22 – Beckman Coulter has signed an agreement to distribute Biopool International- Xtrana's DNA extraction kits with its instrument systems, the companies announced Monday.

Beckman Coulter plans to sell the DNA extraction technology, used in life science research to extract DNA from whole blood, with machines such as the Biomek workstation before the middle of the year, according to Susan Stone, a marketing manager at Beckman Coulter.

As a result of the agreement, Beckman Coulter will have non-exclusive, worldwide rights to Xtrana’s proprietary Xtra Amp extraction kits. Neither company divulged the financial details of the arrangement.

The extraction technology utilizes a solid-phase extraction matrix, known as Xtra Bind, that requires no centrifugation or vacuum filtration. The result is a faster and cheaper process, because the Xtra Amp kits require no additional instrumentation, said Shannon Beard, vice president for technology development at Biopool Xtrana.

“In our case, the DNA physically binds to this crystalline matrix,” said Beard. “Then it just becomes a liquid handling procedure.”

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more